SANGAMO THERAPEUTICS, INC (SGMO) Form 8-K — Jul 1, 2026

$SGMOForm 8-KItems 4.01, 8.01, 9.01Filed Jul 1, 2026, 4:01 PM ET0001193125-26-292501Original filing

Sangamo Therapeutics terminated Ernst & Young LLP as its independent registered public accounting firm on June 25, 2026, following the company's previously announced voluntary petition for relief under Chapter 11 of the Bankruptcy Code. The company noted that Ernst & Young's reports for the fiscal years ended December 31, 2024 and December 31, 2025 contained an explanatory paragraph regarding the company's ability to continue as a going concern but otherwise included no adverse opinions or modifications.

Key figures

Otc Trading Symbol: SGMOQ
Bankruptcy Case Number: 26-10989

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.